SOBI.ST
Swedish Orphan Biovitrum AB (publ) [SOBI.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SOBI.ST Stock Summary
Top 10 Correlated ETFs
SOBI.ST
Top 10 Correlated Stocks
SOBI.ST
In the News
SOBI.ST Financial details
Company Rating
Strong Buy
Market Cap
68.34B
Income
3.16B
Revenue
19.1B
Book val./share
93.93
Cash/share
0.67
Dividend
-
Dividend %
-
Employees
1.61K
Optionable
No
Shortable
Yes
Earnings
18 Jul 2023
P/E
21.59
Forward P/E
-
PEG
-6.34
P/S
3.58
P/B
2.45
P/C
343.88
P/FCF
160.8
Quick Ratio
0.01
Current Ratio
0.7
Debt / Equity
0.94
LT Debt / Equity
0.11
-
-
EPS (TTM)
5.99
EPS next Y
-
EPS next Q
-
EPS this Y
-1.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.11%
Revenue last 5Y
15.51%
Revenue Q/Q
-12.54%
EPS Q/Q
-
-
-
-
-
SMA20
-11.32%
SMA50
-2.08%
SMA100
7.31%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
12%
ROC
0.11%
Gross Margin
77%
Oper. Margin
23%
Profit Margin
17%
Payout
-
Shs Outstand
296.61M
Shs Float
188.35M
-
-
-
-
Target Price
-
52W Range
199.1-273.8
52W High
-15.6%
52W Low
+15.78%
RSI
40
Rel Volume
0.58
Avg Volume
349.15K
Volume
203.86K
Perf Week
-2.04%
Perf Month
-11.79%
Perf Quarter
1.63%
Perf Half Y
7.41%
-
-
-
-
Beta
0.367891
-
-
Volatility
3.6%, 14.69%
Prev Close
-0.17%
Price
230.4
Change
-1.96%
SOBI.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 33.91 | 48.69 | 51.79 | 52.63 | 63.56 | |
| Net income per share | 8.97 | 11.29 | 11.01 | 9.08 | 8.92 | |
| Operating cash flow per share | 7.76 | 12.42 | 17.7 | 18.54 | 15.78 | |
| Free cash flow per share | 5.61 | -20.89 | 4.62 | 17.29 | 10.78 | |
| Cash per share | 11.13 | 2.52 | 1.37 | 3.54 | 4.6 | |
| Book value per share | 33.54 | 57.85 | 68.57 | 78.64 | 89.73 | |
| Tangible book value per share | -4.15 | -70 | -63.07 | -51.58 | -45.63 | |
| Share holders equity per share | 33.54 | 57.85 | 68.57 | 78.64 | 89.73 | |
| Interest debt per share | 0.22 | 57.41 | 50.99 | 38.38 | 32.33 | |
| Market cap | 54.15B | 45.21B | 48.94B | 54.61B | 63.76B | |
| Enterprise value | 51.15B | 61.04B | 63.11B | 64.47B | 71.5B | |
| P/E ratio | 22.4 | 13.68 | 15.08 | 20.39 | 24.17 | |
| Price to sales ratio | 5.92 | 3.17 | 3.21 | 3.52 | 3.39 | |
| POCF ratio | 25.9 | 12.44 | 9.39 | 9.98 | 13.67 | |
| PFCF ratio | 35.8 | -7.4 | 35.93 | 10.71 | 20 | |
| P/B Ratio | 5.99 | 2.67 | 2.42 | 2.35 | 2.4 | |
| PTB ratio | 5.99 | 2.67 | 2.42 | 2.35 | 2.4 | |
| EV to sales | 5.6 | 4.28 | 4.14 | 4.15 | 3.81 | |
| Enterprise value over EBITDA | 14.12 | 10.1 | 10.02 | 11.16 | 11.54 | |
| EV to operating cash flow | 24.47 | 16.8 | 12.1 | 11.79 | 15.33 | |
| EV to free cash flow | 33.82 | -9.99 | 46.34 | 12.64 | 22.43 | |
| Earnings yield | 0.04 | 0.07 | 0.07 | 0.05 | 0.04 | |
| Free cash flow yield | 0.03 | -0.14 | 0.03 | 0.09 | 0.05 | |
| Debt to equity | 0.9 | 1.7 | 1.39 | 1.1 | 0.98 | |
| Debt to assets | 0.47 | 0.63 | 0.58 | 0.52 | 0.49 | |
| Net debt to EBITDA | -0.83 | 2.62 | 2.25 | 1.71 | 1.25 | |
| Current ratio | 0.95 | 1.28 | 0.78 | 1 | 0.75 | |
| Interest coverage | 55.34 | 18.81 | 10.61 | 8.91 | 8.33 | |
| Income quality | 0.86 | 1.1 | 1.61 | 1.66 | 1.4 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0.39 | 0.41 | 0.42 | |
| Research and developement to revenue | 0.12 | 0.1 | 0.1 | 0.13 | 0.13 | |
| Intangibles to total assets | 0.59 | 0.82 | 0.8 | 0.79 | 0.76 | |
| Capex to operating cash flow | -0.28 | -2.68 | -0.74 | -0.07 | -0.32 | |
| Capex to revenue | -0.06 | -0.68 | -0.25 | -0.02 | -0.08 | |
| Capex to depreciation | -1.19 | -6.13 | -1.9 | -0.18 | -0.61 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0 | 0 | |
| Graham number | 82.28 | 121.23 | 130.35 | 126.75 | 134.23 | |
| ROIC | 0.23 | 0.08 | 0.08 | 0.07 | 0.06 | |
| Return on tangible assets | 0.34 | 0.4 | 0.34 | 0.26 | 0.21 | |
| Graham Net | -16.7 | -92.62 | -88.74 | -76.94 | -77.62 | |
| Working capital | -349.16M | 1.58B | -2.28B | 17M | -3.65B | |
| Tangible asset value | -1.12B | -20.48B | -18.59B | -15.22B | -13.49B | |
| Net current asset value | -1.54B | -21.41B | -19.91B | -16.68B | -14.76B | |
| Invested capital | 0 | 0.98 | 0.72 | 0.47 | 0.34 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 422.71M | 583.99M | 625M | 563.5M | 905M | |
| Average inventory | 1.17B | 1.53B | 2.41B | 3.24B | 3.38B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 73.59 | 74.53 | 64.4 | 58.46 | 95.68 | |
| Days of inventory on hand | 194.04 | 193.94 | 345.53 | 358.71 | 254.64 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.96 | 4.9 | 5.67 | 6.24 | 3.81 | |
| Inventory turnover | 1.88 | 1.88 | 1.06 | 1.02 | 1.43 | |
| ROE | 0.27 | 0.2 | 0.16 | 0.12 | 0.1 | |
| Capex per share | -2.14 | -33.3 | -13.07 | -1.25 | -5 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 16.69 | 13.12 | 13.51 | 0 | 17.68 | |
| Net income per share | 1.84 | 0.87 | 1.52 | 0 | 3.6 | |
| Operating cash flow per share | 5.57 | 1.16 | 2.64 | 0 | 6.69 | |
| Free cash flow per share | 5.04 | -0.65 | 0.19 | 0 | -4.3 | |
| Cash per share | 3.6 | 1.22 | 0.97 | 0 | 0.67 | |
| Book value per share | 80.49 | 82.37 | 84.7 | 0 | 93.93 | |
| Tangible book value per share | 80.49 | -50.07 | 84.7 | 0 | 93.93 | |
| Share holders equity per share | 80.49 | 82.37 | 84.7 | 0 | 93.93 | |
| Interest debt per share | 32.77 | 33.38 | 33.95 | 0 | 31.74 | |
| Market cap | 65.82B | 65.32B | 63.8B | 0 | 71.55B | |
| Enterprise value | 74.53B | 74.82B | 73.7B | 7.74B | 80.59B | |
| P/E ratio | 30.3 | 63.3 | 35.37 | 0 | 16.76 | |
| Price to sales ratio | 13.36 | 16.85 | 15.95 | 0 | 13.66 | |
| POCF ratio | 40.04 | 190.45 | 81.8 | 0 | 36.08 | |
| PFCF ratio | 44.26 | -342.01 | 1.14K | 0 | -56.12 | |
| P/B Ratio | 2.77 | 2.69 | 2.55 | 0 | 2.57 | |
| PTB ratio | 2.77 | 2.69 | 2.55 | 0 | 2.57 | |
| EV to sales | 15.13 | 19.3 | 18.43 | 1.29 | 15.38 | |
| Enterprise value over EBITDA | 51.01 | 84.25 | 57.67 | 3.13 | 37.34 | |
| EV to operating cash flow | 45.33 | 218.13 | 94.48 | 4.08 | 40.64 | |
| EV to free cash flow | 50.12 | -391.72 | 1.32K | 4.22 | -63.2 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0.02 | 0 | 0 | 0 | -0.02 | |
| Debt to equity | 1.05 | 0.99 | 1.03 | 0.98 | 0.94 | |
| Debt to assets | 0.51 | 0.5 | 0.51 | 0.49 | 0.48 | |
| Net debt to EBITDA | 5.96 | 10.69 | 7.74 | 3.13 | 4.19 | |
| Current ratio | 1.03 | 1.02 | 0.88 | 0.75 | 0.7 | |
| Interest coverage | -7.61 | 53.83 | -5.18 | 16.66 | 8.85 | |
| Income quality | 2.44 | 1.08 | 1.38 | 1.07 | 1.5 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.42 | 0.34 | 0 | 0 | 0.39 | |
| Research and developement to revenue | 0.12 | 0.16 | 0.13 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.78 | 0.81 | 0.81 | 0.76 | 0.79 | |
| Capex to operating cash flow | -0.1 | -1.56 | -0.93 | -0.03 | -1.64 | |
| Capex to revenue | -0.03 | -0.14 | -0.18 | -0.01 | -0.62 | |
| Capex to depreciation | -0.23 | -0.95 | -1.25 | -0.11 | -4.91 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 57.72 | 40.24 | 53.89 | 0 | 87.24 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | |
| Return on tangible assets | 0.05 | 0.03 | 0.05 | 0.11 | 0.09 | |
| Graham Net | -66.05 | -66.66 | -72.62 | 0 | -81.19 | |
| Working capital | 307M | 162M | -1.07B | -3.65B | -4.41B | |
| Tangible asset value | -14.51B | -14.79B | -16.43B | -13.49B | -14.52B | |
| Net current asset value | -15.69B | -16.06B | -17.77B | -14.76B | -15.78B | |
| Invested capital | 0.41 | 0.41 | 0.41 | 0.34 | 0.33 | |
| Average receivables | 3.59B | 3.44B | 3.19B | 1.62B | 0 | |
| Average payables | 551.5M | 532M | 440M | 806.5M | 938.5M | |
| Average inventory | 3.39B | 3.39B | 3.37B | 3.32B | 3.5B | |
| Days sales outstanding | 68.49 | 72.61 | 73.1 | 0 | 0 | |
| Days payables outstanding | 32.35 | 45.79 | 34.86 | 86.15 | 52.72 | |
| Days of inventory on hand | 199.77 | 302.12 | 319.44 | 229.27 | 308.88 | |
| Receivables turnover | 1.31 | 1.24 | 1.23 | 0 | 0 | |
| Payables turnover | 2.78 | 1.97 | 2.58 | 1.04 | 1.71 | |
| Inventory turnover | 0.45 | 0.3 | 0.28 | 0.39 | 0.29 | |
| ROE | 0.02 | 0.01 | 0.02 | 0.05 | 0.04 | |
| Capex per share | -0.53 | -1.81 | -2.45 | 0 | -11 |
SOBI.ST Frequently Asked Questions
What is Swedish Orphan Biovitrum AB (publ) stock symbol ?
Swedish Orphan Biovitrum AB (publ) is a SE stock and trading under the symbol SOBI.ST
What is Swedish Orphan Biovitrum AB (publ) stock quote today ?
Swedish Orphan Biovitrum AB (publ) stock price is $230.4 today.
Is Swedish Orphan Biovitrum AB (publ) stock public?
Yes, Swedish Orphan Biovitrum AB (publ) is a publicly traded company.
Company Profile
- Volume Average 349.15K
- Market Capitalization 68.34B
- Employee 1.61K
- CEO Dr. Guido Oelkers
- Headquarters Solna,SE
- IPO Date 2021-08-24
-
Website
https://www.sobi.com 
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
